Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foritinib Succinate in Advanced ALK/ROS1-positive NSCLC
NCT04237805Phase 2Recruiting
- Sponsor
- Fosun Pharma
- Start
- Nov 2016
- Primary completion
- Dec 2022
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of foritinib in non-small cell lung cancer (NSCLC) and solid tumor, sponsored by Fosun Pharma. Primary endpoints: Dose Limiting Toxicity at 24 days and Objective Response Rate at 6 months. Started Nov 2016; status: recruiting.
02
Drugs
foritinib
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT04237805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04237805.